Results 231 to 240 of about 46,954 (256)
Some of the next articles are maybe not open access.
Prevalence of relevant multi-drug resistant (MDR) pathogens in a bronchiectasis (BE) cohort
Respiratory infections, 2019Background: 60% of BE patients suffer bronchial infection, leading to frequent antibiotics and high risk of MDR. Aim: to describe the prevalence of MDR S. aureus (SA) and P. aeruginosa (PA) in a cohort of BE patients from Barcelona (Spain). Methods: Inclusion criteria: age ≥18y, documented BE, at least 1 sputum culture along 2018. According to EUCAST
Javier Perez +7 more
openaire +1 more source
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia?
European Respiratory Journal, 2011Pneumonia caused by MDR pathogens is becoming a worldwide problem difficult to manage.The aim was to investigate whether in pneumonia MDR infection is associated with acute respiratory failure (ARF) development or with a higher mortality. We retrospectively investigated patients with CAP or HCAP who had been admitted to Fondazione ...
Seghezzi, S +6 more
openaire +2 more sources
Atypical multi-drug resistance (MDR)
Anti-Cancer Drugs, 1993Verapamil, cyclosporin A (CsA), the cyclosporin derivative SDZ PSC 833 and the novel cyclopeptolide SDZ 280-446 were tested for their capacity to chemosensitize a P-glycoprotein (Pgp)-expressing multi-drug resistant (MDR) variant of the CEM human T lymphoblastoid cell subline (CCRF ACTD 400+).
B, Jachez, F, Loor
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2017
India accounts for 25% of the global burden of MDR-TB. In 2016, the India's Revised National TB Control Programme reported a success rate of 46% among 19,298 MDR-TB patients treated under the programme. This suboptimal treatment outcome warrants an urgent need for newer drugs and newer regimens in the treatment of MDR-TB.
Muniyandi, Malaisamy +1 more
openaire +3 more sources
India accounts for 25% of the global burden of MDR-TB. In 2016, the India's Revised National TB Control Programme reported a success rate of 46% among 19,298 MDR-TB patients treated under the programme. This suboptimal treatment outcome warrants an urgent need for newer drugs and newer regimens in the treatment of MDR-TB.
Muniyandi, Malaisamy +1 more
openaire +3 more sources
Outcome of Multi drug resistant(MDR)TB patients on Shorter MDR TB Regimen
Tuberculosis and non-tuberculous mycobacterial diseases, 2023Jyoti Bajpai +12 more
openaire +1 more source
Effects of two benzo[a]phenothiazines on multi-drug resistance (mdr) and tumor antigen expression. [PDF]
Anticancer research, 1995 Two benzo[a]phenothiazines 5H-benzo[a]phenothiazin-5-one (1), and its derivative 6-methyl-5H-benzo[a]phenothiazin-5-one (2) inhibited the proliferation of human and mouse tumor cell lines. The multi-drug resistant (mdr) subline was more sensitive than its parent cell line to 5H-benzo[a]phenothiazin-5-one (1), 6-methyl-5H-benzo[a]phenothiazin-5-one (2 ...
Molnár József +4 more
openaire +1 more source
Formulation strategy to overcome multi-drug resistance (MDR)
Archives of Pharmacal Research, 2011openaire +2 more sources
Multi-drug-resistant- (MDR-) and extensively-drug-resistant- (XDR-) tuberculosis in Germany
Pneumologie, 2008C Lange +17 more
openaire +1 more source
Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
Cancer Letters, 2014Zhiping Yang +2 more
exaly